OnKure Therapeutics (OKUR) News Today $2.45 +0.01 (+0.41%) Closing price 04:00 PM EasternExtended Trading$2.38 -0.07 (-3.02%) As of 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock OKUR Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 Time Period Companies Like OnKure Therapeutics (NASDAQ:OKUR) Could Be Quite RiskyAugust 19, 2025 | finance.yahoo.comCompanies Like OnKure Therapeutics (NASDAQ:OKUR) Could Be Quite RiskyAugust 19, 2025 | finance.yahoo.comAnalysts Offer Insights on Healthcare Companies: OnKure Therapeutics (OKUR) and AbCellera Biologics (ABCL)August 15, 2025 | theglobeandmail.comOnKure Therapeutics reports Q2 EPS ($1.14), consensus ($1.25)August 12, 2025 | msn.comOnKure Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Business UpdateAugust 12, 2025 | globenewswire.comOKUR OnKure Therapeutics, Inc.June 12, 2025 | seekingalpha.comInsider Selling: OnKure Therapeutics (NASDAQ:OKUR) Major Shareholder Sells 1,813,439 Shares of StockMay 20, 2025 | insidertrades.comOnKure Therapeutics (NASDAQ:OKUR) Major Shareholder Cormorant Asset Management, Lp Sells 24,300 SharesMay 15, 2025 | insidertrades.comMajor Shareholder Sells Thousands of OnKure Therapeutics Shares!May 14, 2025 | tipranks.comPromising Developments and Positive Trial Results Reinforce Buy Rating for OnKure TherapeuticsMay 9, 2025 | tipranks.comOnKure Therapeutics, Inc.: OnKure Therapeutics Reports First Quarter 2025 Financial Results and Business HighlightsMay 6, 2025 | finanznachrichten.deOnKure Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights | OKUR ...May 6, 2025 | gurufocus.comOnKure Therapeutics Reports First Quarter 2025 Financial Results and Business HighlightsMay 6, 2025 | gurufocus.comOnKure Therapeutics Reports First Quarter 2025 Financial Results and Business HighlightsMay 6, 2025 | globenewswire.comOnKure Therapeutics (OKUR) Receives Outperform Rating from Evercore ISI | OKUR Stock NewsApril 30, 2025 | gurufocus.comOnKure Therapeutics, Inc. Class A Common Stock (OKUR) ChartsApril 16, 2025 | nasdaq.comAisling Capital Management LP Invests $762,000 in OnKure Therapeutics (NASDAQ:OKUR)April 3, 2025 | marketbeat.comHighbridge Capital Management LLC Makes New $3.44 Million Investment in OnKure Therapeutics (NASDAQ:OKUR)March 29, 2025 | marketbeat.comQ1 EPS Estimate for OnKure Therapeutics Decreased by AnalystMarch 21, 2025 | marketbeat.comOnKure Therapeutics (OKUR) Expected to Announce Quarterly Earnings on ThursdayMarch 20, 2025 | marketbeat.comHC Wainwright Has Lowered Expectations for OnKure Therapeutics (NASDAQ:OKUR) Stock PriceMarch 19, 2025 | marketbeat.comOnKure Therapeutics price target lowered to $34 from $40 at H.C. WainwrightMarch 18, 2025 | markets.businessinsider.comPromising Outlook for OnKure Therapeutics: Strategic Developments and Market Expansion Plans for 2025March 18, 2025 | tipranks.comWill OnKure Therapeutics (NASDAQ:OKUR) Spend Its Cash Wisely?March 12, 2025 | finance.yahoo.comOptimistic Buy Rating for OnKure Therapeutics Driven by Promising OKI-219 Development and Future ProspectsMarch 12, 2025 | tipranks.comOnKure Therapeutics Reports Progress and FinancialsMarch 11, 2025 | tipranks.comOnKure Therapeutics reports Q4 EPS ($1.37), consensus (86c)March 10, 2025 | markets.businessinsider.comOnKure Therapeutics price target lowered to $30 from $35 at OppenheimerMarch 10, 2025 | markets.businessinsider.comOnKure Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business HighlightsMarch 10, 2025 | markets.businessinsider.comOnKure Therapeutics Reports Progress on PIKture-01 Trial and Expands PI3Ka Franchise with Upcoming Development Candidate AnnouncementMarch 10, 2025 | quiverquant.comQOnKure Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business HighlightsMarch 10, 2025 | globenewswire.comOnKure Therapeutics to Present at Upcoming Leerink and Stifel Investor ConferencesMarch 4, 2025 | globenewswire.comDeep Track Capital, LP Acquires Shares in OnKure Therapeutics IncFebruary 14, 2025 | gurufocus.comHighbridge Capital Management LLC Acquires Significant Stake in OnKure Therapeutics IncFebruary 7, 2025 | gurufocus.comJonesTrading Reaffirms Their Buy Rating on OnKure Therapeutics (OKUR)February 6, 2025 | markets.businessinsider.comVanguard Group Inc's Strategic Acquisition of OnKure Therapeutics SharesJanuary 31, 2025 | gurufocus.comJones Trading Initiates Coverage of OnKure Therapeutics (OKUR) with Buy RecommendationJanuary 30, 2025 | msn.comOnKure Therapeutics initiated with a Buy at JonesResearchJanuary 29, 2025 | markets.businessinsider.comJones Trading sets OnKure stock Buy rating, $32 targetJanuary 29, 2025 | msn.comOnKure Therapeutics, Inc. (OKUR)January 7, 2025 | finance.yahoo.comOnKure Therapeutics Inc Class A Shares OKURDecember 22, 2024 | morningstar.comMOppenheimer Remains a Buy on OnKure Therapeutics (OKUR)December 12, 2024 | markets.businessinsider.comOnKure Therapeutics announces safety, pharmacokinetic data on OKI-219December 11, 2024 | markets.businessinsider.comOnKure Therapeutics Reports Positive Preliminary Data From First-in-human Study Of OKI-219December 10, 2024 | markets.businessinsider.comOnKure Therapeutics Advances Cancer Drug TrialsDecember 10, 2024 | tipranks.comOnKure Announces Encouraging Preliminary Safety, Tolerability, and Pharmacokinetic (PK) Data from its First-In-Human PIKture-01 Trial of OKI-219December 10, 2024 | globenewswire.comLeerink Partners Initiates Coverage of OnKure Therapeutics (OKUR) with Outperform RecommendationDecember 5, 2024 | msn.comOnKure Therapeutics Inc Class A SharesDecember 5, 2024 | morningstar.comMOnKure Therapeutics Reports Strategic Merger and Financial UpdatesNovember 26, 2024 | markets.businessinsider.comOnKure Announces New Date for Upcoming Investor CallNovember 25, 2024 | globenewswire.com Get OnKure Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for OKUR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. OKUR Media Mentions By Week OKUR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. OKUR News Sentiment▼1.890.93▲Average Medical News Sentiment OKUR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. OKUR Articles This Week▼11▲OKUR Articles Average Week Get the Latest News and Ratings for OKUR and Related Stocks Enter your email address to receive the latest news and analysts' ratings for OnKure Therapeutics and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Cybin News Citius Oncology News Molecular Partners News Cardiff Oncology News Alpha Cognition News Zura Bio News Forte Biosciences News MEI Pharma News Invivyd News TuHURA Biosciences News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:OKUR) was last updated on 9/12/2025 by MarketBeat.com Staff From Our PartnersStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredCritical AI announcement set to ignite AI 2.0I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredDo NOT Day Trade (Do THIS instead)Forget day trading (especially in markets like these). Trade OVERNIGHT instead! I've uncovered a shockin...Monument Traders Alliance | SponsoredWall Street laughed at Trump’s “Smart Dollar.” Now they’re all in."THIS is the Biggest Economic Story of 2025" While most Americans are focused on tariffs and inflation, the...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OnKure Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share OnKure Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
